Metformin promotes susceptibility to experimental Leishmania braziliensis infection

BACKGROUND: Metformin (MET) is a hypoglycemic drug used for the treatment of diabetes, despite interference in host immunity against microorganisms. Cutaneous infection caused by pathogens such as Leishmania braziliensis (Lb), the agent responsible for cutaneous leishmaniasis (CL) in Brazil, represe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mem Inst Oswaldo Cruz
Päätekijät: Lima, Filipe Rocha, Ferreira, Lais de Melo, Malta, Tainá Alves, Bonyek-Silva, Icaro, Santos, Reinan Lima, Tavares, Natália Machado, de Carvalho Filho, Edgar Marcelino, Arruda, Sérgio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Instituto Oswaldo Cruz, Ministério da Saúde 2020
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7668079/
https://ncbi.nlm.nih.gov/pubmed/33206822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1590/0074-02760200272
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia